While none of the included probands had detectable virus-specific antibody titers on the day of vaccine administration, all tested individuals had robust S1-IgG levels at a median of 30 days (range 23-32) post-COVID-19 vaccination (Fig. 1a). The gene discussed is PSMD1; the disease is COVID-19.